Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas

Stopped early · Phase 1

Conditions studied: Intraductal Papillary Mucinous Neoplasms

In brief

1. To assess the effect of RG1068 at a dose of 0.2 mcg/kg intravenously (IV) on the diameter of the pancreatic duct when used during Magnetic Resonance Pancreatography 2. To demonstrate that RG1068-enhanced MRCP improves detection and characterization of intraductal papillary mucinous neoplasms (IPMN) relative to unenhanced MRCP in patients with suspected IPMN 3. To correlate findings on MRCP with histologically confirmed malignancy

Key facts

Study ID
NCT00621556
Run by
Massachusetts General Hospital
People needed
2
Starts
2008-02-01
Expected to finish
2008-12-01
Last updated by the study team
2009-01-29

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.